

## **Discontinuation of Isolation**

**For people who are [moderately ill](#) and not moderately or severely immunocompromised:**

- Isolation and precautions can be discontinued 10 days after symptom onset (day 1 through day 10, with day 0 being the first day of symptoms).

**For people who are [severely ill](#) and not moderately or severely immunocompromised:**

- 20 days after symptom onset (with day 0 being the first day of symptoms) **and** after resolution of fever for at least 24 hours (without the use of fever-reducing medications) **and** improvement of other symptoms.

**For people who are [moderately or severely immunocompromised](#) (regardless of COVID-19 symptoms or severity):**

- Resolution of fever for at least 24 hours (without the use of fever-reducing medication) and improvement of other symptoms. **AND**
- Negative results from at least two consecutive respiratory specimens collected  $\geq 24$  hours apart (total of two negative specimens) tested using an **antigen test (LAB8666)**
- Re-testing using an **antigen test (LAB8666)** for SARS-CoV-2 infection is suggested if symptoms worsen or return after ending isolation and precautions.

**Moderate and severe immunocompromising conditions and treatments include but are not limited to:**

- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppressive therapy)
- Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection (people with HIV and CD4 cell counts less than  $200/\text{mm}^3$ , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)
- Active treatment with high-dose corticosteroids (i.e., 20 or more mg of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory